SynPath and the NovoSorb technology is an alternative that is being used in other markets, and increasingly used as some of those applications that I mentioned earlier, as well as the clinical evidence that is being built. We have a pathway there. It is a large market of number of patients. I think that one piece of evidence showed that there were 880,000 of those of a particular procedure within skin cancer repair that are performed every year in the U.S., and we believe we have a good option in SynPath to fill the needs of those patients and the caregivers. We are looking at being very deliberate, so we have to make sure we have the evidence, make sure we have a clinical differentiator, and make sure that the economics make sense for the providers as well.
Yep, that all makes sense. Thanks, Bruce. We have talked about BTM, we have talked about SynPath, so maybe if we swing into MTX on this side now. The presentation identified accelerating MTX adoption as another important growth lever that you have. What are you learning from the markets, and where has it gained early traction so far? What needs to happen for it to become a more meaningful part of the portfolio?
Definitely very happy with the progress of MTX. It has been in the market for a little over two years in the U.S. particularly, and in other markets as well. Australia is a good example. What we are seeing is very much it fits perfectly in that space of expanding into complex wound applications. The versatility of MTX, which is the NovoSorb platform without the temporizing layer that is part of BTM, gives it a lot more flexibility to be used in these complex cases that potentially are a very deep wound that they need help with volumetric fill, and that provide an option that BTM couldn't do. It was very well received that it is being moved into some of these indications.
I think what is surprising to us, and is very promising, is that as MTX is moving into these markets, we are finding out a few things, that yes, there is a specific place for MTX, but there are also applications where we are seeing MTX used in combination with BTM. MTX is using to fill the defect and then BTM to seal off the wound. Really, for the first time now, it is more of a platform play where we are selling two products into the one procedure. What we have also found now is that the accounts, MTX grew at 90% last year-on-year growth, very strong growth off a lower base.
We see that growth faster than if we compare it to how BTM grew all the years ago when it started, which is unsurprising, because the NovoSorb technology and the trust that we've built with BTM now benefits the adoption of MTX. We're also seeing now accounts that are using BTM that have adopted MTX. I think it's over almost 300 accounts now in the U.S. that are using MTX. They're actually using more BTM as well. We're getting into the details of why that's happening, but we do believe part of it is also that it's used in combination.
Yep, that all makes sense. Jan, I've neglected you a little bit, so I might throw this question to you. Underlying EBITDA grew considerably faster than revenue in FY 2026. As PolyNovo continues investing in new products and markets, how should investors think about the scope for further operating leverage and margin expansion?
Yeah, sure. I think the underlying EBITDA is a good demonstration of the leverage that is coming through in the business, in the P&L. That's going to continue to increase in conjunction with our focus on driving top-line growth and investing in that, all in conjunction, obviously, with the things we're doing in R&D. Gross margins back up over 90%. We've got the, I guess, the resources to invest in both areas, but at the same time, still be able to expand our EBITDA margin. The business certainly has scale, and we're continuing to penetrate all our existing markets and get more out of our teams, more out of all the markets we operate in. A perfect example is, I've now got two products that sales reps are selling, either with BTM and MTX.
Immediately, we're seeing the impact there on the average sales per rep increasing. I expect that to continue. We're really comfortable with consensus and where that sits, particularly now four months into the year. Yeah, expect to see EBITDA margin increase in line with at a faster rate than revenue growth.
Bruce and Jan, unfortunately, that brings us to the end of our time. It has been a fantastic conversation, and thank you for joining us and providing some further insight into the opportunities ahead for PolyNovo.
Great. Thank you so much.
Thanks for the opportunity.
To our audience, don't go anywhere. We have one last presentation for the day, and we will be back shortly just after this. Hello, and welcome back to the Bell Potter Healthcare Conference. Closing out today's program is Aroa Biosurgery, ticker is ARX. Joining me is the company's founder and CEO, Dr. Brian Ward. Brian, welcome to the conference.
Brenton, great to be here. Thank you.
For those new to Aroa, their business spans several areas of tissue repair. Myriad is used in the operating theater for complex surgical wounds. Between them, Endoform and Symphony address chronic and acute wounds in outpatient care. Through its partnership with TELA Bio, Aroa's technology is also used in the OviTex portfolio for hernia and soft tissue reconstruction. What connects all these products is AROA ECM. It is a biological material derived from sheep tissue. It preserves much of the original tissue's natural structure and proteins, and helps create an environment that supports the body's own repair process. Importantly for investors, Aroa has already grown into a profitable business, with annual revenues exceeding NZD 100 million, and it is now investing in a larger U.S. sales presence to build on that position. Brian, welcome once again.
I will hand over to you to tell us more, and then we will come back for some questions.
All right. Thanks, Brenton. I will just skip through these slides, relatively quickly. Just a little bit of background. As Brenton says, we are a soft tissue recon company. Most of our sales are in the U.S. Just in terms of results last year and scale, we just did just over NZD 104 million. We were profitable, NZD 12 million of profit, cash flow positive, NZD 5 million. We are now at a stage where we are able to scale the company profitably, and we are really looking at building out the organization in the U.S. We are about 300 people, 200 people based in Auckland, and then another 100 people based up in the U.S., predominantly a commercial organization.
In terms of our priorities this year, we've had a great run with Myriad over the last 18 months or so, continuing to build out the momentum with Myriad, improving our sales force productivity, getting more out of each of our sales team. We have a new option in chronic wounds called Symphony, and we'll talk a little bit about that later. Getting deeper penetration within our accounts, we're at the early stages of adoption in hospitals, and we think there's a long way to run for Myriad in terms of use across a wide range of specialties, improving our penetration in accounts. Also more use within individual hospitals, within hospital systems. Many of the hospitals that we're in are members of corporate owners where they have tens of hospitals, improving our traction with those IDNs or hospital groups.
Just in terms of guidance for the coming year, guidance is between NZD 115 million and NZD 125 million, and we'll be profitable this year between NZD 8 million and NZD 11 million EBITDA. Just in terms of the technology, as Brenton said, it's a biological material derived from sheep forestomach, has the benefit of having a structure that allows cells to migrate into it, but also biology that is conducive to rapid tissue formation. This is really the platform technology that all of the products are built on, and that platform is incredibly versatile, and I think that's a key theme for Aroa in terms of, it's a platform company, and that platform can be leveraged in a number of different ways.
Our thesis is that this material is relevant to a wide range of applications in regenerative healing, so we have a common technology, can be used in multiple markets. There's multiple ways in which we can commercialize this product, and every time we do that, we build the base of evidence and the capability to be more efficient in future applications. Not a single shot on goal, but a company that has many growth options in front of it, and we've executed on a number of these already. It's reusable, this biological material, we can use it to develop a range of different formats. The evidence that we generate for this and the applications that we're in tends to carry forward into applications, so it gives us a degree of scalability.
We know that this technology has great regenerative performance, it's better outcomes, it's a lower cost of care for hospitals, certainly a product that surgeons prefer to use, and it's a business that can be profitably scaled. The platform's already commercially validated, so our Myriad product is growing very strongly in soft tissue reconstruction, particularly in trauma and lower limb salvage. Symphony is a relatively new product for us. We've got some great clinical evidence that's been generated in that area. Endoform's probably, it's a longstanding product that we've had, and we've recently entered into a partnership there with one of the largest global wound care companies to broaden our reach with that. Then we have a partnership with TELA Bio in hernia and breast, as Brenton said earlier. As I said before, there's a portfolio of commercial opportunities here, not just one single bet.
We already have some products in the market. Symphony is a new option for us. We have some other opportunities bubbling away, internally, with some good commercial interest in those, and then some adjacent opportunities as well, so using our material in completely new applications, and ENIVO, another platform technology that we have, is an example of that. The great thing about this technology is that the economics compound over time, so we have a lot of the capability in place in terms of the science, the manufacturing, and the clinical evidence, that every time we develop a new product, we can leverage that, and the cost of commercialization, what is required in terms of bringing those new products to market is a lot lower each time, so the economics become more and more favorable.
We are also building a great moat in terms of evidence, so a lot of good evidence that cuts across all of the platform that allows us to reuse that every time we move forward with a different product. It is one platform, multiple value engines. It is proven, it is differentiated, it is very scalable, it is flexible, lots of options. And we have had great disciplined execution in terms of commercializing this and showing that this platform has a huge potential to generate a very strong business. I am going to go back to you now, Brenton. Thank you.
Perfect. Thanks for the overview there, Brian. Brian, Aroa is stepping up its investment in its direct U.S. sales capability this year. Maybe starting with Myriad, why is now the right time to make that investment, and what should investors be watching to determine whether that is working?
Yeah. I think we have a team of 55 sales reps in the U.S., and we have been really focusing on improving their effectiveness over the last 18 months. We have been successful to get to where we are now by employing experienced people, but we are now at a stage we want to make that more scalable. So we have brought in some senior leaders, some new, very experienced commercial leaders to help us with that. The timing is right because we have got great evidence in place. If you look at Myriad, we have been running a registry there to deliver prospective evidence to show that Myriad is very effective in trauma and lower limb salvage. That body of evidence is there. We have proven out that we can scale the organization. We are profitable, we are cash flow positive, and we have grown strongly.
It is really a time now to take advantage of that and scale up and increase our presence in the U.S.
Thanks, Brian. You are also investing NZD 4 million behind Symphony at a time when the U.S. skin substitute market is in the middle of a significant reimbursement reset, and many companies are coming under pressure. Before I finish and get to the question on that, I might just give a little context for the audience at home. The outpatient skin substitute market in 2019 was about a $250 million market, and now going forward to 2024, that increased from there to about a $10 billion market is what it was. You saw a 40-fold increase in the market there, and that was with a lot of companies coming in on that side with some predatory pricing, just putting things in the $500-$4,000 per centimeter squared price range.
The CMS saw this, came in, cut the knees out, and said, "No, thank you. We do not want any of that." All of these companies in here have now seen a lot of price compression. They had products that now cannot compete in this market, and we have seen a lot of disruption and a lot of companies exiting this market. Specifically, just if you go look up some of them, you get the likes of Organogenesis on that side, they are down, they are worth a tenth of what they were. MiMedx this year, they are down 50%, they are worth 1/2 of what they were. All these companies that were very highly leveraged and now are seeing a lot of exposure, and they are now seeing a lot of pain on that side.
To my question, Brian, why does Aroa see those same changes as an opportunity, and what advantages does Symphony have in that market?
Yeah, it's a great question. I think many of the companies that have been in this market, their business models were predicated on very, very high pricing. They encouraged physicians to use the highest priced products because physicians were being paid as a percentage of the ASP. Those business models were never going to be sustainable in the long term. CMS has done two things. It's cut the pricing. Pricing is now capped at $127 and change per square centimeter. It's still a high price, but they've also signaled that clinical evidence is going to be increasingly important. What we see is a market, whereby there's a bunch of companies whose business models are no longer sustainable.
There's been a lot of players in this market as well that have been opportunistic in terms of being there, but they were small-scale companies that could never really compete at reasonable pricing levels. We're well-positioned in this market. Our costs of manufacture are very low, so we have a lot of flexibility on pricing. Our clinical evidence is excellent. We've just published a RCT with great results. What we see is many companies exiting from this market, the competitive intensity changing, and it being a market that there's three or four strong companies that can be effective, and we think Aroa is well-placed to be one of those. Another change that you're seeing here is the shift of patients back into the hospital outpatient department, rather than being treated in the physician's office.
I think the previous incentives encouraged patients or encouraged physicians to treat patients in their offices. Our footprint's been designed around a hospital-based presence, and so already having those hospital relationships, having those GPO contracts, being present in the hospital is giving us the ability to be able to compete within the hospital environment. Everything's resetting. The environment's changing, and I think, if you look at what's going to be required in order to be successful in the future, you're going to need to have a good product at a reasonable price, great clinical evidence, and you're going to need to have a presence in the hospital, and you're going to need to have coverage there. I think that very well aligns with where we're at.
Thanks, Brian. Maybe just one more point to that as well. I know you spoke to clinical evidence. You've recently released your RCT data for Symphony on that side, and that showed great results on that part. In part on that is some LCDs that were removed. When I say LCDs for the audience, I'm talking about local coverage determinations, which are set by the Medicare Administrative Contractors. These were put there in place to determine who gets reimbursement and what bar or threshold you need to pass to be eligible for reimbursement. One of the things that they put in there was RCT data as a requirement, and it was a very strict process, but they ended up pulling this just before it went because about 18 of about 330 companies were eligible for reimbursement under this method.
Brian, this now puts you in that bucket, and a lot of companies that we've seen, speaking to those same ones, those MiMedx, Integra, Organogenesis, they've all spoken and said that they expect some form of this LCD to come back in. What's your thoughts there, and do you think that would then cause another market consolidation from that?
Yeah, I think so. I think there's a lot of change still to kind of work its way through in this market. They withdrew the LCDs, but I think it was a strong signal from CMS that they are going to put in place requirements, and it could be at a local level through the Medicare Administrative Contractors, but it could also be at a national level. We expect a requirement for RCTs to come in place. Medicare's said that they're not going to do that in 2027, but we'd be very surprised if that doesn't come into place in 2028. That's going to lead to another shakeout within this. I think the other thing is just looking at the quality of evidence.
There are RCTs out there, and I think Medicare's going to look very closely at those, and I think there's a range of quality in terms of those RCTs as well. One of the things we've done purposefully in the Symphony RCT is really set it up so that the study's very robust. We've treated a wider range of patients, so both Wagner Grade 1 and Wagner Grade 2, so that's really an indication of how severe their DFUs are. We've made sure that the study's well-powered. There's a large number of patients that the difference between the treated and untreated group is really robust and significant as well. We think that study, when you look across the studies in this area, we feel like that study is a very robust study and puts us in good stead for the future.
Perfect. Thank you, Brian. Now we might move on to your commercial partner in TELA Bio. Now, they're still a very important partner despite the fact that you're now moving more towards those direct sales businesses. But in recent times, they've faced a bit of some challenges on their side. They brought in Heather Getz. She's doing what seems to be a great job in restructuring the business and cost-cutting and, kind of, getting them through to their next stage. But how should investors be thinking about OviTex and Aroa's exposure to that channel now?
Yeah, it's a good question. Look, I think investors have for some time worried about TELA Bio and sustainability. There's been a history there of raising capital and then burning through the capital and having to go back to investors and raise more capital. I mean, they have done a great job in terms of growing that business to $80 million U.S. in revenue, but that's sort of flattened out a little bit for them over the last couple of years, and I think there's a couple of reasons for that. They've had some challenges with some contracting in hospitals. We think that's fixable, and I know that they're working their way through it. What Heather's done is she's come in and she has taken $17 million of cost out of the business.
By doing that, she's extended their runway and given them some time to prove the business out more. I think that's a good change. I think there's a number of things that could happen there. I think number one is OviTex is a great product, in terms of the outcomes, and I think they've built, between the two of us, we've built a very strong asset there that's valuable for the future. TELA Bio, we are very supportive of TELA Bio. We'd like to see them trade through to profitability and kind of reshape the business and be successful. I think that's one option. I think another option is that there could be some strategic action there where another partner comes in or there's large strategic investment that could help them. We think that's an option as well.
Or it may take a little bit more time, and it may be that we see some sort of sales process. I think there's some options that could play out there. Hard to say which of these will play out. I mean, we certainly would like to back TELA to find their way through this. But I think irrespective of which of those scenarios play out, we do think that there's a bright future for OviTex. We think that the clinical outcomes that you see with OviTex, particularly in complex hernia, where there's a very high rate of recurrence, typically, that can be anywhere between 10% and 30%. You're seeing with OviTex, recurrence rates less than 3%. That product has a lot of merit, and we think it's got a good future in front of it.
Yeah. Thanks, Brian. That's some great color. Maybe if we move on, you've recently announced that arrangement that you just stepped into with Mölnlycke. That agreement gives Endoform a different route to the market in the U.S. What capabilities and customer reach does Mölnlycke bring, and how will you assess whether that partnership is delivering?
Yeah. It is early days. We, as a small company, have had a limited amount of resource, so we made the choice when we set up our commercial organization in the U.S. to really focus on the inpatient setting. It was something that was more obtainable for us to access. Endoform really languished. We really put no effort into it, but surprisingly maintained a good base of sales there. We have been thinking for a while about how we really get more from Endoform. We have had, for some time now, been talking to Mölnlycke about how we might do that. So, we have entered into a partnership with them in the U.S. They are, I think they are number four in the world. They have got a very strong presence in the U.S. They have built out a post-acute sales team. They have got a very strong reputation there.
Endoform is a nice complement to their existing portfolio. So, we think that can really allow Endoform to really lift up the level of sales. Certainly, they have got the reach to do that, they have got the portfolio to do that, they have got good reach into distributor networks as well. I think it is really, probably starting next calendar year, really starting to see some traction with Endoform. It is a great arrangement for us. We do not have sales expense. It is all incremental revenue that comes in, essentially drops to the bottom line. So, I think it can really add to profitability over the coming years.
Yeah, makes sense. Brian, the platform, and when I say the platform, I am talking about the Aroa ECM. The platform gives Aroa a growing number of potential products, indications, and commercial models. What criteria do you use to decide which opportunities to pursue and then which ones not to fund?
Yeah, it is a good question. I think there is a few things. So, we certainly have to make sure that our direct sales team, where we are investing a lot of money, have a competitive portfolio. I think around Myriad and around Symphony, there are line extensions that are important in order to be able to address the variety of use cases in soft tissue recon. So, I think there we are building out some line extensions. Outside of that, there is a range of other opportunities in soft tissue recon. I think it depends on the size of the market, what is required in order to develop that product and commercialize that product, and how realistic we think it is for us to obtain a reasonable market share. So, I think those things that are most adjacent to us are the easiest for us to address.
There are some other opportunities outside of the areas that we are operating where there is some fast-growing markets that we could potentially address with partners. It is really a prioritization around market opportunity and returns.
Yep. Maybe I will just swing back a little bit, but we have touched on that increase in commercial investment you have made while remaining profitable. How should investors think about the timing of the return on that spending and the potential operating leverage that can come through once that sales platform reaches scale? Because obviously, it will need to scale up and build.
Yeah. I mean, I think for us, our main focus is the things that we are doing now and making sure that we are growing top line strongly, the operating leverage is coming through, and the EBITDA margins are increasing. I think we see that over the next two to three years, getting stronger and stronger. I mean, we are tracking above 20% in terms of top- line growth. We see EBITDA margins going above 20% as well. I think that starts to come through pretty rapidly. Last year, there was a strong performance. This year, we have chosen to make a bigger investment in terms of in that commercial organization. That was, what we see really, as a sort of a one-off fixed investment in leadership and a bit of sales headcount as well.
But I think as we look forward beyond this year, we should see those EBITDA margins increasing. I think the other thing that's coming through there is just sales force effectiveness as well. Seeing sales productivity improve.
Thanks, Brian. Maybe one last thing that I think it might be worthwhile shining a bit of light on, it doesn't get spoken about as much, is you do have a morselized product or a particulate. For the people, I'll let you explain actually, sorry, for the people listening. But what we've seen from the rest of the market there is Integra on their side speaking to, that's obviously a market segment that's growing and growing quite substantially, but they had a lot of control there and they're seeing some pressure come through on their end there now. MiMedx tried to acquire Sanara MedTech on that side, largely for one part to get more exposure to the hospital inpatient side and not that outpatient exposure that they had, but a large part because that was one of the products that they had.
Can you just speak to your side on that and what your experiences are?
Yeah, it's interesting, isn't it? We have a morselized product and I've got a couple of different versions of that. It's something that we commercialized two or three years ago. Before that, we were mainly doing matrix-type sheets, and what we've seen is the morselized product grow really rapidly. It's 70% of our revenue. It's used across a broad range of indications. What we see with it is just a faster response, typically. It tends to just get this bolus of biology that really makes a difference quite quickly, but also it's good in uneven wounds. I think it's a really important part of the sales mix, and its versatility is great as well. I think the, certainly morselized products, there's a wide range of applications for them, and it's a product that is easy to apply, surgeons love it.
Yep. Brian, unfortunately, we are out of time, so we will leave it there. Thank you for joining us and taking us through what looks to be a really exciting next stage of growth for Aroa.
Thanks, Brenton. It is great to join you.
With that, we have reached the end of day two of the Bell Potter Healthcare Conference. A sincere thank you to all of today's presenters and everyone who joined us across the day. The conference returns tomorrow morning at 8:30 A.M. for our third and final day, with another strong lineup of healthcare companies still to come. Thanks again for your time today, and we look forward to welcoming you back tomorrow morning.